While FLT3-ITD is a well-recognized poor prognostic factor in AML, significantly diminishing both disease-free survival (DFS) and overall survival (OS), the FLT3-TKD (Tyrosine Kinase Domain) point mutation has demonstrated an inconsistent prognostic impact [6,7,8,9]. Here, FLT3 is linked to acute myeloid leukemia.